Lifmior
etanercept
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Lifmior has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
This EPAR was last updated on 20/02/2020
Authorisation details
| Product details | |
|---|---|
| Name |
Lifmior
|
| Agency product number |
EMEA/H/C/004167
|
| Active substance |
etanercept
|
| International non-proprietary name (INN) or common name |
etanercept
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
L04AB01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Europe MA EEIG
|
| Revision |
8
|
| Date of issue of marketing authorisation valid throughout the European Union |
13/02/2017
|
| Contact address |
Boulevard de la Plaine 17 |
Product information
05/04/2019 Lifmior - EMEA/H/C/004167 - IG/1082
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Immunosuppressants
Therapeutic indication
Therapeutic indication
- Rheumatoid arthritis;
- Juvenile idiopathic arthritis
- Psoriatic arthritis;
- Axial spondyloarthritis;
- Plaque psoriasis;
- Paediatric plaque psoriasis.